Publicacións nas que colabora con Carlos Panizo Santos (32)

2024

  1. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

2020

  1. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

2019

  1. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2016

  1. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

    Immunologic Research, Vol. 64, Núm. 2, pp. 548-557

  2. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

2015

  1. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403

2010

  1. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

    Blood, Vol. 116, Núm. 14, pp. 2531-2542

2009

  1. Prolonged idiotypic vaccination against follicular lymphoma

    Leukemia and Lymphoma, Vol. 50, Núm. 1, pp. 47-53

2008

  1. Systemic lupus erythematosus and Franklin's disease: When the somatic mutation mechanism makes a mistake

    Rheumatology

2007

  1. Anemia in chronic lymphatic leukemia: is erythropoietin the solution?

    Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 1, pp. 3-10

  2. La anemia en la leucemia linfática crónica: ¿es la eritropoyetina la solución del problema?

    Revista de medicina, Vol. 51, Núm. 1, pp. 3-10

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

2004

  1. Past, present and future of anti-idiotype vaccination

    Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23

2003

  1. Estrategias terapéuticas con vacunas idiotípicas en el tratamiento del linfoma folicular

    Hematologia - Citocinas, Inmunoterapia y Terapia Celular, Vol. 6, Núm. 3, pp. 175-182